Skip to main content
Top
Gepubliceerd in:

01-06-2000 | Artikelen

Toepassing van meervoudige antiretrovirale therapie bij een kind in een vergevorderd stadium van aids

Auteurs: M. I. Gaakeer, A. M. C. vanRossum, N. G. Hartwig, R. deGroot

Gepubliceerd in: Tijdschrift voor Kindergeneeskunde | Uitgave 3/2000

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Summary

New antiretroviral treatments for children infected with human immunodeficiency virus (hiv) and suffering from acquired immunodeficiency syndrome (aids) are evolving rapidly. As a consequence of highly active anti-retroviral treatment hiv and aids in children in Western countries is changing from a fatal to a chronic disease. In the majority of patients, it is possible to reduce the viral load in blood and tissues. This process is accompanied by (partial) recovery of the immune system and significant improvement in the quality of life. In this article the case history of an 18-year-old girl is described. The patient was infected with hiv-1 soon after birth by blood transfusion and developed aids at the age of 12 years. This case serves to illustrate the enormous and sustained clinical improvement which may be achieved by application of highly active anti-retroviral treatment in children with an advanced stage of aids.
Literatuur
go back to reference UNAIDS/WHO. Aids epidemic update: December 1998. New York: WHO, 1998. UNAIDS/WHO. Aids epidemic update: December 1998. New York: WHO, 1998.
go back to reference Prevention CDC. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Official authorized addenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting icd-9-cm. mmwr 1994;43:1019. Prevention CDC. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Official authorized addenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting icd-9-cm. mmwr 1994;43:1019.
go back to reference Hogg RS, Heath KV, Yip B, et al. Improved survival among hiv-infected individuals following initiation of antiretroviral therapy. jama 1998;279: 450-4.CrossRefPubMed Hogg RS, Heath KV, Yip B, et al. Improved survival among hiv-infected individuals following initiation of antiretroviral therapy. jama 1998;279: 450-4.CrossRefPubMed
go back to reference Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with hiv-1. Lancet 1998;352:1725-30.CrossRefPubMed Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with hiv-1. Lancet 1998;352:1725-30.CrossRefPubMed
go back to reference Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma hiv rna and cd4+ lymphocyte count in hiv-infected infants and children. jama 1998;279(10):756-61.CrossRefPubMed Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma hiv rna and cd4+ lymphocyte count in hiv-infected infants and children. jama 1998;279(10):756-61.CrossRefPubMed
go back to reference Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficienty virus type 1. Women and infants transmission study group. N Engl J Med 1997;336:1337-42.CrossRefPubMed Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficienty virus type 1. Women and infants transmission study group. N Engl J Med 1997;336:1337-42.CrossRefPubMed
go back to reference Rossum ACM van, Niesters HGM, Geelen SPM, et al. Clinical and virologic response to combination treatment with indinavir, zidovudine and lamivudine in hiv-1 infected children: a multicentre study in The Netherlands. J Pediatr, in press. 2000. Rossum ACM van, Niesters HGM, Geelen SPM, et al. Clinical and virologic response to combination treatment with indinavir, zidovudine and lamivudine in hiv-1 infected children: a multicentre study in The Netherlands. J Pediatr, in press. 2000.
go back to reference Emery S, Lane HC. Immune reconstitution in hiv infection. Curr Opinion Immunol 1997;9:568-72.CrossRef Emery S, Lane HC. Immune reconstitution in hiv infection. Curr Opinion Immunol 1997;9:568-72.CrossRef
go back to reference Li TS, Tubiana R, Katlama C, et al. Long-lasting recovery in cd4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced hiv-1 disease. Lancet 1998;351:1682-86.CrossRefPubMed Li TS, Tubiana R, Katlama C, et al. Long-lasting recovery in cd4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced hiv-1 disease. Lancet 1998;351:1682-86.CrossRefPubMed
go back to reference Powderlu WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy. jama 1998;280: 72-7.CrossRef Powderlu WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy. jama 1998;280: 72-7.CrossRef
go back to reference Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced hiv-1 disease (see comments). Lancet 1998;351:252-5.CrossRefPubMed Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced hiv-1 disease (see comments). Lancet 1998;351:252-5.CrossRefPubMed
go back to reference Hicks CB, Meyers SA, Giner J. Resolution of intractable molluscum contagiosum in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with Ritonavir. cid 1997;24: 1023-5. Hicks CB, Meyers SA, Giner J. Resolution of intractable molluscum contagiosum in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with Ritonavir. cid 1997;24: 1023-5.
go back to reference Dieleman JP, Hillebrand-Haverkort ME, Ende ME van der, et al. Lipodystrofie en ‘buffalo hump’ bij de behandeling met hiv-proteaseremmers. Ned Tijdschr Geneeskd 1998; 142:2856-60.PubMed Dieleman JP, Hillebrand-Haverkort ME, Ende ME van der, et al. Lipodystrofie en ‘buffalo hump’ bij de behandeling met hiv-proteaseremmers. Ned Tijdschr Geneeskd 1998; 142:2856-60.PubMed
go back to reference Kop JB, Miller KD, Mican JAM, et al. Crytalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997;127:119-25. Kop JB, Miller KD, Mican JAM, et al. Crytalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997;127:119-25.
go back to reference Faulds D, Brogden RN. Didanosine. A review of its antiviral activity pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs 1992; 44(1):94-116.CrossRefPubMed Faulds D, Brogden RN. Didanosine. A review of its antiviral activity pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs 1992; 44(1):94-116.CrossRefPubMed
go back to reference Lea AP, Faulds D. Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in hiv infection. Drugs 1996;51:846-64.CrossRefPubMed Lea AP, Faulds D. Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in hiv infection. Drugs 1996;51:846-64.CrossRefPubMed
go back to reference Maxon CJ, Greenfield SM, Turner JL. Acute pancreatitis as a common complication of 2', 3'-dideoxyinosine therapy in the acquired immunodeficiency syndrome. Am J Gastroenterol 1992;87:708-13. Maxon CJ, Greenfield SM, Turner JL. Acute pancreatitis as a common complication of 2', 3'-dideoxyinosine therapy in the acquired immunodeficiency syndrome. Am J Gastroenterol 1992;87:708-13.
go back to reference Perelson AS, Neumann AU, Markowitz M, et al. hiv-1 Dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-6.CrossRefPubMed Perelson AS, Neumann AU, Markowitz M, et al. hiv-1 Dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-6.CrossRefPubMed
go back to reference Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373: 117-22.CrossRefPubMed Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373: 117-22.CrossRefPubMed
go back to reference Ho DD, Neumann AU, Perelson As, et al. Rapid turnover of plasma virions and cd4 lymphocytes in hiv-1 infection. Nature 1995. Ho DD, Neumann AU, Perelson As, et al. Rapid turnover of plasma virions and cd4 lymphocytes in hiv-1 infection. Nature 1995.
go back to reference Bebenek K, Abbotts J, Roberts JD, et al. Specificity and mechanism of error-prone replication by human immunodeficiency virus-1 reverse transcriptase. J Biol Chem 1989;264:16948-56.PubMed Bebenek K, Abbotts J, Roberts JD, et al. Specificity and mechanism of error-prone replication by human immunodeficiency virus-1 reverse transcriptase. J Biol Chem 1989;264:16948-56.PubMed
go back to reference Erickson JW, Gulnik SV, Markowitz M. Protease inhibitors: resitance, cross-resistance, fitness and the choice of initial and salvage therapies. aids 1999;13:(suppl a):s189-204.PubMed Erickson JW, Gulnik SV, Markowitz M. Protease inhibitors: resitance, cross-resistance, fitness and the choice of initial and salvage therapies. aids 1999;13:(suppl a):s189-204.PubMed
go back to reference Gezondheidsraad. Commissie Kanalisering van aidsbehandeling. CKv. Resistentievorming bij het gebruik van hiv-remmenede geneesmiddelen. 1998/07. Gezondheidsraad. Commissie Kanalisering van aidsbehandeling. CKv. Resistentievorming bij het gebruik van hiv-remmenede geneesmiddelen. 1998/07.
Metagegevens
Titel
Toepassing van meervoudige antiretrovirale therapie bij een kind in een vergevorderd stadium van aids
Auteurs
M. I. Gaakeer
A. M. C. vanRossum
N. G. Hartwig
R. deGroot
Publicatiedatum
01-06-2000
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Tijdschrift voor Kindergeneeskunde / Uitgave 3/2000
Print ISSN: 0376-7442
Elektronisch ISSN: 1875-6840
DOI
https://doi.org/10.1007/BF03061301

Andere artikelen Uitgave 3/2000

Tijdschrift voor Kindergeneeskunde 3/2000 Naar de uitgave